In the pursuit of innovative therapeutic strategies, by pharmacologically targeting the HBP/EIF3H/YAP axis, we demonstrate the feasibility of reactivating the degradation process of YAP, thereby enhancing the potency of chemotherapeutic agents and impeding tumor progression. The gene discussed is EIF3H; the disease is neoplasm.